Your browser doesn't support javascript.
loading
[18F]-fluoromisonidazole (FMISO) PET/MRI hypoxic fraction distinguishes neuroinflammatory pseudoprogression from recurrent glioblastoma in patients treated with pembrolizumab.
Barajas, Ramon F; Ambady, Prakash; Link, Jeanne; Krohn, Kenneth A; Raslan, Ahmed; Mallak, Nadine; Woltjer, Randy; Muldoon, Leslie; Neuwelt, Edward A.
Affiliation
  • Barajas RF; Department of Radiology, Neuroradiology Section, Oregon Health & Science University, Portland Oregon, USA.
  • Ambady P; Knight Cancer Institute Translational Oncology Program, Oregon Health & Science University, Portland, Oregon, USA.
  • Link J; Neuro-Oncology and Blood-Brain Barrier Program, Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA.
  • Krohn KA; Center for Radiochemistry Research, Oregon Health & Science University, Portland, Oregon, USA.
  • Raslan A; Center for Radiochemistry Research, Oregon Health & Science University, Portland, Oregon, USA.
  • Mallak N; Department of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, USA.
  • Woltjer R; Advanced Imaging Research Center, Oregon Health & Science University, Portland Oregon, USA.
  • Muldoon L; Department of Pathology, Oregon Health & Science University, Portland, Oregon, USA.
  • Neuwelt EA; Neuro-Oncology and Blood-Brain Barrier Program, Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA.
Neurooncol Pract ; 9(3): 246-250, 2022 May.
Article in En | MEDLINE | ID: mdl-35601969
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline Language: En Journal: Neurooncol Pract Year: 2022 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline Language: En Journal: Neurooncol Pract Year: 2022 Type: Article Affiliation country: United States